Skip to main content
Clinical Trials/NCT02471625
NCT02471625
Unknown
Not Applicable

Traumatic Brain Injury (TBI) Feasibility Study to Determine Possible Prognostic Indicators as Provided by the EPIC ClearView™

Epic Research & Diagnostics, Inc.1 site in 1 country200 target enrollmentApril 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Traumatic Brain Injury
Sponsor
Epic Research & Diagnostics, Inc.
Enrollment
200
Locations
1
Primary Endpoint
Agreement of ClearView Scan versus Active Diagnosis
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this research study is to evaluate whether data made by the ClearView System can be used to detect whether someone has a traumatic brain injury and how severe the injury is.

Detailed Description

Traumatic brain injury (TBI) is a significant cause of death and disability in the U.S. The severity of a TBI may range from "mild" (i.e. a brief change in mental status or consciousness) to "severe" (i.e. an extended period of unconsciousness or memory loss after the injury). However, most TBI's that occur each year are mild and are commonly called concussions. Unfortunately, TBI terminology does not adequately describe the injury or impairment, its treatment, or the resulting outcomes. Due to the complexity of the human brain, each person's physiology can result in different patterns of impairment and secondary conditions, requiring different treatment or rehabilitation. The intent of EPIC ClearView™ TBI Feasibility (EPIC-011) is to collect data to further develop the ClearView™ Response Scale to measure electrophysiology associated with TBI

Registry
clinicaltrials.gov
Start Date
April 2015
End Date
May 2016
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Epic Research & Diagnostics, Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Suspected TBI population:
  • Acute head trauma within 24-72 hours of presentation
  • 18-65 age inclusive
  • GCS of 3-15 on initial evaluation in ED
  • Control population:
  • 18-65 age inclusive
  • GCS score of 15

Exclusion Criteria

  • Current neurological disease
  • Current severe psychological disorder
  • History of substance or alcohol abuse
  • Under drug or alcohol influence, if so, must wait at least 24 hrs. prior to consent
  • Documented current diagnosis/treatment of cancer (including Sickle Cell Disease)
  • Current treatment to the head/brain (radiation, whole brain therapy, gamma knife)
  • Head injury in the last two years
  • Unwilling to sign informed consent
  • Pregnant or potentially pregnant
  • Pacemaker, automatic implanted cardiac defibrillator or other implanted electrical device

Outcomes

Primary Outcomes

Agreement of ClearView Scan versus Active Diagnosis

Time Frame: I day unless TBI population chooses to participate in one week follow up

The EPIC ClearView software produces a Response Scale report that summaries the electrophysiological measurements associated with organ systems. The autonomic numbers indicate how the person's stress response is affecting different body systems and the physical numbers reflect physiological function. These measurements will then be compared to TBI diagnosis, based on one or two possible scans

Secondary Outcomes

  • Comparison of TBI subjects to Controls(1 day unless TBI population chooses to participate in one week follow up)

Study Sites (1)

Loading locations...

Similar Trials